Marc B.
- Country
- France
- Department
- Service de Néphrologie et Hémodialyse
Research Overview
- THINK - intensification of blood pressure lowering Therapeutics based on diuretics versus usual management for uncontrolled Hypertension IN patients with moderate to severe chronic Kidney disease: an open label, cluster randomized controlled, phase 3 trial
- Phase III Randomized Double‑Blind Placebo‑Controlled Trial of Elecoglipron (AZD5004) on Renal Decline and Mortality in Adults with Chronic Kidney Disease
- Evaluation of Irbesartan on Cardiovascular and Global Outcomes Post-Acute Kidney Injury in ICU-Discharged Patients: A Randomized, Double-Blind, Multicenter Trial
Data & Insights
Has run more than one trial at 95 of 442 partner sites.
Specializations
Chronic Kidney Disease Management
The investigator specializes in treating complex renal conditions, with particular emphasis on chronic kidney disease (CKD) and its progression. Their research encompasses various stages of kidney disease, from moderate to end-stage renal disease (ESRD).
- CKD with Hypertension
- Advanced CKD Management
- Cardiovascular Complications in CKD
Specialized Renal Conditions
This clinical investigator focuses on specific kidney disorders, particularly IgA Nephropathy (IgAN) and ANCA vasculitis. Their work extends to studying innovative therapeutic approaches for these conditions.
- Immunological Kidney Disorders
- Proteinuria Management
- Immunosuppressive Therapy
Acute Kidney Injury
The investigator has notable expertise in acute kidney injury (AKI) treatment and recovery, particularly in post-intensive care settings. Their research includes investigation of therapeutic interventions for improving outcomes after AKI.
- Post-ICU Kidney Recovery
- Cardiovascular Outcomes
- Therapeutic Intervention Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.